Home Companies Catalysts Deep Dives
AZD0120 AZD0120 PHASE1
Drug Profile
ModalityCAR-T
RouteIV
Therapy AreaOncology
Formulations[]
Companies
AZN (ORIGINATOR)100%
Programs (1)
IndicationStageKey StudyRegional Status
Solid tumorsPHASE1—[]
Notes
CD19/BCMA dual CAR-T for multiple myeloma.
Data from Supabase · Updated 2026-03-24